Iovance Biotherapeutics (IOVA) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 432.7%.
| ASSET | % RETURN |
|---|---|
Iovance Biotherapeutics (IOVA) | 432.73% |
Immunitybio (IBRX) | 336.14% |
Veradermics (MANE) | 323.03% |
MaxLinear (MXL) | 321.42% |
Erasca (ERAS) | 307.55% |
Abcellera Biologics (ABCL) | 298.83% |
Pulse Biosciences (PLSE) | 288.07% |
CareDx (CDNA) | 282.86% |
AXT (AXTI) | 274.3% |
Okeanis Eco Tankers (ECO) | 251.77% |
Kodiak Sciences (KOD) | 247.69% |
Oruka Therapeutics (ORKA) | 216.63% |
Aehr Test Systems (AEHR) | 207.04% |
Penguin Solutions (PENG) | 205.84% |
Spyre Therapeutics (SYRE) | 204.49% |
Ringcentral (RNG) | 198.94% |
Enliven Therapeutics (ELVN) | 188.9% |
Hyperliquid Strategies Inc Common Stock (PURR) | 182.44% |
Definium Therapeutics (DFTX) | 182.22% |
PBF Energy (PBF) | 173.09% |
International Seaways (INSW) | 165.78% |
Iridium Communications (IRDM) | 165.51% |
Maravai Lifesciences Holdings (MRVI) | 159.94% |
Calumet Specialty Products Partners (CLMT) | 152.35% |
Tango Therapeutics (TNGX) | 151.19% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.